Update (9:35 a.m.): Updated with Tuesday market open information.
The stock was down 12.57% to $41.75 at 9:33 a.m. on Tuesday.
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Here's a technical look at how to trade some of the most active stocks on the market right now.
The FDA granted accelerated approval for Clovis Oncology's (CLVS) rucaparib drug.